Checking for immunotherapy drugs in gynecological cancer patients
Part of Cancer, Immune system & allergy, Women’s health & pregnancy clinical trials.
This study looks at whether small amounts of immunotherapy drugs can be found in the blood or other body fluids of people with gynecological cancers. It may help doctors better understand how these treatments work in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed gynecological cancer (like ovarian, uterine, cervical, or vulvar cancer).
- You are currently receiving or are scheduled to receive immunotherapy as part of your cancer treatment.
- You are at least 18 years old and can provide a blood or other biological sample.
- You have not had prior treatment with monoclonal antibodies that could affect the results.
- You are not pregnant or breastfeeding, and have no other active cancers or serious health issues that might interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how gut bacteria may relate to how well immunotherapy works in people with advanced or returning gynecologic cancer. You may be asked to give stool samples several times so researchers can measure changes in your gut microbiome.
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
This study looks at tumor tissue and blood samples to find biological “markers” in people with gynecologic cancers. It may help researchers understand disease better and could guide future, more personalized treatments.
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
This trial looks at how a blood inflammation marker (CRP) changes when people with metastatic gynecologic cancers receive immunotherapy, sometimes together with palliative chemotherapy. The goal is to see patterns that may help doctors better understand and manage treatment responses to immunotherapy.
This study looks for new markers in the blood or tumor that could predict how well immunotherapies work for advanced digestive and gynecological cancers. It includes people getting immunotherapy, chemotherapy, or targeted therapy, and also those with certain liver or abdominal metastases that can be surgically removed after chemo.
Hear when a new Gynecological Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.